Эргокальциферол

Quick links

Choose a section

Quick links to important sections

Advertisements

Эргокальциферол

Selected form

Advertisements
Advertisements

Treatment option: Osteoporosis, Rickets

Advertisements

Overview of Эргокальциферол

What is Ergocalciferol?

Ergocalciferol, also known as vitamin D2, is a fat-soluble vitamin that plays a fundamental role in maintaining the body's mineral balance. It is a form of vitamin D found primarily in plant-based sources and certain fungi. Unlike vitamin D3, which the human body synthesizes through skin exposure to ultraviolet radiation, ergocalciferol is typically acquired through the diet or supplementation.

Biological Function

The primary biological function of ergocalciferol involves the regulation of calcium and phosphorus levels in the bloodstream. Once ingested, it undergoes metabolic conversion in the liver and kidneys to become biologically active. This active form facilitates the absorption of calcium from the intestines and helps manage the mineralization of bone tissue. By supporting these processes, ergocalciferol contributes to the maintenance of skeletal integrity and dental health.

Role in the Body

Beyond its structural role in the skeletal system, ergocalciferol is involved in several physiological processes, including:

  • Bone Metabolism: It assists in the continuous process of bone remodeling and growth.
  • Mineral Homeostasis: It helps maintain the precise concentrations of minerals required for normal cellular function and nerve signaling.
  • Parathyroid Regulation: It aids in managing the activity of the parathyroid glands, which are responsible for monitoring calcium levels in the body.

Ergocalciferol is commonly used to address nutritional gaps when dietary intake or natural vitamin D production is insufficient to meet physiological demands.

Advertisements

What side effects are possible with Эргокальциферол?

Possible Side Effects and Safety Information

The official safety profile for Ergocalciferol (Vitamin D2) is primarily defined by the risk of Hypervitaminosis D (toxicity) and the resulting high blood calcium levels (Hypercalcemia). As a fat-soluble vitamin, its effects can persist for two or more months after cessation of treatment, a specific pattern noted in regulatory documentation.


Adverse Reaction Spectrum and Organ Classes

The majority of documented adverse reactions are manifestations of toxicity. These are grouped by the affected system in regulatory labels, although specific frequency classifications (e.g., 'common', 'rare') are often designated as Incidence Not Known:

  • Gastrointestinal Disorders: May include nausea, vomiting, loss of appetite (anorexia), and metallic taste.
  • Renal and Urinary Disorders: Manifestations of increased mineral load, such as excessive urination (polyuria) and excessive thirst (polydipsia), are listed.
  • Nervous System Disorders: Documented effects include nervousness and confusion.

Serious Adverse Reactions and Safety Constraints

The most serious adverse reactions center on the consequences of severe accumulation. These include: Severe Hypercalcemia, which can lead to cardiac arrhythmias, and Nephrocalcinosis (calcification of the kidneys), potentially causing irreversible renal insufficiency.

Contraindications strictly prohibit the use of Ergocalciferol in individuals with pre-existing Hypercalcemia, Hypervitaminosis D, or a diagnosis of Malabsorption Syndrome.

Special safety considerations are noted for Infants and Children, where excessive doses can lead to a decline in linear growth and increased bone mineralization. Caution is also advised for Pregnant and Nursing Mothers, requiring careful monitoring if high doses are administered.

The regulatory labels necessitate routine blood and urine tests to check for unwanted effects, particularly monitoring serum calcium and other measures of Vitamin D status.

Advertisements

Overdose and Emergency Response

The overdose state for Ergocalciferol (Vitamin D2) is officially classified as Hypervitaminosis D, stemming from the accumulation of the fat-soluble vitamin. This toxicity is principally characterized by hypercalcemia (elevated blood calcium). Documented manifestations are systemic, including anorexia, nausea, and vomiting, alongside increased urination and thirst (polyuria and polydipsia), muscle weakness, and neurological signs such as stupor and confusion.

Overdosage is associated with severe systemic sequelae. Regulators document life-threatening outcomes such as irreversible renal insufficiency, cardiac arrhythmias, and hypertension. Chronic overdosage carries the risk of widespread calcification of soft tissues, including the heart and blood vessels. Infants and young children are a population-specific consideration, with chronic overdose linked to a decline in linear growth.

Upon suspicion of toxicity, immediate withdrawal of the vitamin is required, and patients must seek emergency medical attention. Immediate calling of emergency services is required for severe symptoms such as collapse. Treatment is officially defined as symptomatic and supportive, as no specific antidote is known. Management procedures require frequent monitoring of serum calcium and continuous ECG monitoring during vigorous treatment.

Advertisements

Therapeutic Uses of Эргокальциферол

Ergocalciferol (Vitamin D2) is commonly used to help with conditions characterized by systemic imbalance and noticeable physiological strain. It may be part of symptomatic management for conditions involving systemic or localized discomfort.


Addressing Bone Softening and Skeletal Fragility

The medication is commonly used across conditions involving defective bone mineralization, relevant for easing symptoms associated with Rickets in growing individuals and Osteomalacia in adults, as well as refractory rickets. It provides supportive therapeutic benefit that helps address the underlying nutritional deficit, which generally assists with maintaining structural stability and helps ease the overall symptom load of skeletal weakness and bony deformities.

Quick Fact: Relief for Musculoskeletal Symptoms It is relevant for managing symptoms related to physical discomfort that interfere with daily functioning, such as chronic bone pain or muscle weakness.


Managing Chronic Mineral Imbalances and Associated Aches

Ergocalciferol is relevant for easing symptoms related to systemic imbalance in chronic conditions such as Hypoparathyroidism and specific mineral disorders associated with Chronic Kidney Disease (CKD). By assisting in the management of systemic imbalance, it helps alleviate symptoms of increased neurological or muscular activity, including diffuse muscular aches and proximal muscle weakness. It contributes to supporting general well-being during symptomatic phases.

“It is commonly used across conditions presenting with acute episodes of Hypocalcemia or conditions where functional stability becomes affected.”

Supporting Patients with Malabsorption and Dietary Constraints

This form of Vitamin D is commonly used for patients in conditions involving systemic or localized discomfort, such as Cystic Fibrosis or those with chronic kidney disease (CKD). As a plant-sourced vitamin D, it may be part of symptomatic management for severe vitamin D deficiency in vegan and vegetarian patient groups requiring additional symptomatic support.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Ergocalciferol (Vitamin D2)

The official eligibility for Ergocalciferol is strictly defined by regulatory authorities, primarily concerning the patient's existing mineral status to prevent toxicity.

Category Official Regulatory Statements
Populations for whom use is contraindicated Patients with pre-existing Hypercalcemia (high blood calcium), Hypervitaminosis D (excessive Vitamin D levels), abnormal sensitivity to Vitamin D, or known Hypersensitivity to the drug or its components.
Age-related eligibility rules Pediatric Use: The medicine is used in children, including for Rickets, but dosage must be highly individualized. Geriatric Use: Safety is considered established, though data on differential responses in patients over 65 may be insufficient in some studies.
Condition-specific eligibility rules Use requires caution and close patient monitoring in individuals with Renal Impairment/Kidney Disease, Heart Disease, Arteriosclerosis, Sarcoidosis, and Hyperphosphatemia.
Pregnancy and lactation eligibility status Pregnancy: Doses exceeding the Recommended Dietary Allowance (RDA) are generally not recommended or avoided. Lactation: Use requires caution; infant serum calcium monitoring is required if the mother is on high therapeutic doses.

Connection to the overall eligibility profile

Official labeling restricts use when there is evidence of pre-existing Vitamin D excess or high calcium, which are absolute contraindications. Use is permitted for adults and children but must be closely monitored in populations with specific health conditions, such as those with impaired kidney function, due to the increased risk of toxicity.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ergocalciferol's interaction profile is primarily defined by its effects on mineral homeostasis and its absorption and metabolism pathways, as documented in official prescribing information.

Documented Interaction Patterns

Category Interacting Substances and Official Outcomes
Pharmacodynamic Interactions Thiazide Diuretics and Calcium Supplements increase the risk of hypercalcemia due to an additive effect on mineral balance. Co-administration with Digitalis Glycosides may precipitate cardiac arrhythmias if hypercalcemia occurs. Magnesium-containing antacids carry a specific risk of hypermagnesaemia in patients on chronic renal dialysis.
Exposure-Altering Interactions Bile Acid Sequestrants (e.g., Cholestyramine) and Mineral Oil may reduce the gastrointestinal absorption of Ergocalciferol. Glucocorticoids are documented to decrease the therapeutic effect of Vitamin D. Anticonvulsants (e.g., Phenytoin) can increase the rate of Vitamin D metabolism, resulting in increased Vitamin D requirements.
Timing & Restrictions Other Vitamin D Preparations are restricted from co-administration due to the cumulative risk of adverse effects. No specific mandatory timing separation rules are documented for the Ergocalciferol monoproduct.

The official interaction statements classify these effects as clinically significant, particularly noting the specific risk of hypercalcemia in hypoparathyroid patients taking thiazide diuretics. These regulatory constraints highlight the need to consider potential additive mineral effects and changes in vitamin exposure.

Advertisements

Mechanism of Action

Эргокальциферол (Ergocalciferol), or vitamin D2, functions as a prohormone, requiring two sequential hydroxylation steps to become biologically active. It is initially transported to the liver, where the cytochrome P450 enzyme CYP2 R1 mediates the first hydroxylation at the C-25 position, converting it to 25-hydroxyergocalciferol (ercalcidiol). This metabolite then circulates to the kidney.

In the kidney, the mitochondrial enzyme CYP27 B1 (1-alpha-hydroxylase) performs the second, rate-limiting hydroxylation at the C-1 position, yielding the hormonal and primary active form, 1,25-dihydroxyergocalciferol (ercalcitriol).

Ercalcitriol acts as an agonist for the intracellular Vitamin D Receptor (VDR), a ligand-activated nuclear transcription factor present in target cells of the intestine, bone, and kidney. Upon ligand binding, the activated VDR forms a heterodimer complex with the Retinoid X Receptor ( RXR). This complex translocates to the nucleus and binds to specific Vitamin D Response Elements (VDREs) within the DNA promoter regions of target genes.

This binding event modulates the transcription rate of genes that regulate calcium and phosphate transport. The system-level physiological consequence is the coordinated modulation of calcium and phosphate homeostasis across the gastrointestinal tract (enhanced absorption), the kidneys (increased reabsorption), and the bone (mobilization).

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Ergocalciferol (Vitamin D2) administration is patterned by established protocols, emphasizing individualized dosing and specific intake conditions. The medicine is primarily given via the Oral route, using capsules, tablets, or liquid solution; the Intramuscular (IM) injection route is reserved for patients with severe malabsorption syndromes.

Usage Parameter Regulatory Instruction
Standard Dosing Highly individualized, requiring close medical supervision. For Hypoparathyroidism in adults, a range of 50,000 to 200,000 IU is typically administered daily.
Frequency Pattern Can be daily for maintenance or chronic conditions, or intermittent (e.g., weekly) for high-dose repletion courses.
Administration Timing Due to its fat-soluble nature, the medicine is best absorbed when taken after a meal.
Concomitant Use Adequate dietary calcium intake or calcium supplements are necessary for clinical response in conditions like hypoparathyroidism and rickets.

Administration Specifics and Constraints

The dosage level for all patients must be individualized and is subject to readjustment based on ongoing clinical monitoring, especially since the range between therapeutic and potentially harmful doses can be narrow. For liquid forms, the dose must be measured carefully using the provided dropper. Capsules must be swallowed whole and should not be chewed or crushed. For older adult patients, official prescribing information advises that dose selection should be cautious, typically initiating therapy at the low end of the established dosing range.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Ergocalciferol


Evidence for Addressing Vitamin D Deficiency and Bone Mineralization

Research has studied for Ergocalciferol (Vitamin D2) as it relates to addressing low Vitamin D status, a condition known as hypovitaminosis D, and conditions such as Rickets in children and Osteomalacia in adults. Randomized controlled trials (RCTs) and systematic reviews are the primary study types was studied for this area. These studies monitored outcomes related to systemic or functional imbalance by measuring key biomarkers, primarily serum 25-hydroxyvitamin D [25(OH)D] concentration, which is the primary clinical biomarker monitored in research.

Research explored short-term changes in these biomarkers during study periods involving Ergocalciferol in deficient populations. Studies reported measurements of an increased 25(OH)D concentration during the study period. Additionally, research describes patterns related to a subsequent decrease in Parathyroid Hormone (PTH) levels, which was observed in some studies of deficient patients. Historical and observational data contribute to the broader evidence landscape, showing patterns related to changes in classic bone-softening conditions in children.


Research Examining Secondary Hyperparathyroidism

Clinical research was evaluated in specific patient groups where Vitamin D deficiency contributes to conditions involving systemic or functional imbalance, such as secondary hyperparathyroidism. Systematic reviews and controlled trials research examined patterns in PTH levels that were observed during study periods involving Ergocalciferol. Studies primarily monitored PTH concentration alongside changes in serum 25(OH)D and other minerals like calcium and phosphate.

Specifically, research describes patterns related to a measurable shift in PTH concentration measured following Ergocalciferol use in deficient patients with secondary hyperparathyroidism. This evidence contributes to understanding symptom patterns by tracking changes in these specific endocrine biomarkers. Follow-up durations were limited in many of these trials, and sample sizes were modest, meaning the evidence for definitive long-term clinical outcomes remains insufficient.


Comparative Research and Uncertainties

The evidence comparing D2 to D3 suggests that D2 may demonstrate a shorter half-life and appears to lead to a less sustained elevation of 25(OH)D levels when measured against D3 in some studies. Furthermore, data for certain groups remain insufficient, especially for long-term health outcomes following the observed changes in biomarkers. The evidence highlights what is known about addressing deficiency but provides limited information on the impact of D2 supplementation alone on researching potential long-term clinical endpoints such as all-cause mortality or fragility fracture incidence in the general population.

Key Studies & References

  1. Ergocalciferol Drug Information (Vitamin D2)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Эргокальциферол (FAQ)

Q: Is Эргокальциферол a vitamin or a hormone?

Official descriptions define Ergocalciferol as Vitamin D2, which is classified as a fat-soluble vitamin. However, its action in the body is that of a prohormone, meaning it must first be converted into its active hormonal form to function as a crucial regulator of calcium and phosphorus metabolism.

Q: Is it safe to use Эргокальциферол while taking medicines for heart conditions?

Official information regarding interactions notes that co-administration with a specific type of heart medicine, Digitalis Glycosides, carries a risk. This combination may precipitate cardiac arrhythmias (irregular heartbeats) if the patient develops high blood calcium levels (hypercalcemia). Regulatory information defines these effects, and monitoring is required when such conditions are present.

Q: Is there a regulatory safety classification for using Эргокальциферол during pregnancy?

In the United States, this medicine is typically classified as Pregnancy Category C. Regulatory documents advise that doses exceeding the recommended dietary allowance (RDA) during normal pregnancy are generally advised to be avoided. The labeling indicates that use during pregnancy is subject to careful medical assessment and monitoring.

Q: Can children or infants be given Эргокальциферол?

Yes, the use of Ergocalciferol in children, including infants (0-12 months), is described in official documents, particularly for the treatment of conditions like rickets. Regulatory guidelines emphasize that pediatric doses must be highly individualized and carefully monitored.

Q: What happens if a person misses a dose of Эргокальциферол?

Patient counseling information suggests taking a missed dose as soon as it is remembered. However, if it is near the time for the next scheduled dose, the missed dose should be skipped entirely. Patient information cautions against doubling the dose to catch up.

Q: Is it necessary to take Эргокальциферол with food?

The medicine is a fat-soluble vitamin. According to regulatory administration guidelines, it is described as being best absorbed into the body when it is taken immediately after a meal.

Q: Can Эргокальциферол be crushed or split if the person has trouble swallowing pills?

Regulatory documents state specific instructions for different forms of the medication. For capsules, the documents state that they must be swallowed whole and should not be chewed or crushed before swallowing.

Q: How long does the body store Эргокальциферол?

Regulatory documents related to safety and overdosage note that the effects of administered vitamin D can persist in the body for two or more months after the patient stops treatment. This is due to its fat-soluble nature and storage in the body.

Q: What is the general guidance on using alcohol while on Эргокальциферол?

Official labeling does not universally mandate a specific warning against alcohol, but general caution is advised. This is because alcohol consumption can potentially affect overall nutrient status, including Vitamin D levels.

Q: What conditions is Эргокальциферол typically used to treat according to official sources?

Official indications for use include the treatment of specific medical conditions such as hypoparathyroidism, refractory rickets (vitamin D-resistant rickets), and familial hypophosphatemia. It is used in these instances to help regulate mineral balance.

Q: How quickly can one expect to see an effect from taking Эргокальциферол?

The medicine must first be metabolized into its active form by the liver and kidneys. Regulatory clinical pharmacology sections note that the initiation of action in the body involves a time lag, typically between 10 to 24 hours after administration.

Q: Is it common to experience stomach upset when first starting Эргокальциферол?

Official adverse reaction information lists gastrointestinal symptoms, including nausea, vomiting, and constipation. These effects are often reported as typically manifestations associated with high calcium levels.

Q: Are there specific food groups that are known to interact with Эргокальциферол?

Yes, official warnings advise that the consumption of grapefruit and grapefruit juice may alter the blood levels and effects of the medicine. Patients may also need to adjust their dietary intake of foods containing calcium and phosphate.

Q: Does Эргокальциферол affect blood tests?

Yes, the medication is designed to regulate calcium and phosphorus levels in the body. For this reason, regulatory documents require routine blood and urine tests, particularly the monitoring of blood calcium and phosphorus levels, when high therapeutic doses are used.

Q: Can Эргокальциферол be used by people who follow a vegan diet?

Ergocalciferol (Vitamin D2) is chemically derived from ergosterol, a provitamin found in plant and fungal sources. Due to this specific origin, official information notes that it is considered a suitable supplement choice for vegetarian and vegan patient groups.

Q: Does taking Эргокальциферол affect sleep or energy levels?

While not a common general side effect, adverse reaction information lists drowsiness and confusion as potential signs of overdosage or toxicity (hypervitaminosis D). These effects could impact sleep or energy levels.

Q: Is it necessary to avoid certain types of food when taking this medicine?

Official warnings state that patients may be required to adjust their dietary intake of foods containing natural or added calcium, phosphate, and vitamin D. It is also advised to be cautious about consuming grapefruit or grapefruit juice.

Q: Do regulatory agencies classify Эргокальциферол as a high-risk medication?

Regulatory documents note that the range between a therapeutic dose and a toxic dose (Hypervitaminosis D) is narrow. This requires careful, individualized adjustment of the dosage and frequent patient monitoring.

Q: How does Эргокальциферол differ from cholecalciferol in terms of sourcing?

Ergocalciferol (Vitamin D2) is derived from plant and fungal sources, specifically ergosterol. Cholecalciferol (Vitamin D3) is structurally different and is traditionally sourced from animal products, such as lanolin from sheep's wool.

Q: Are headaches a common concern reported with the use of Эргокальциферол?

Headache is listed in official documents as a potential symptom of overdosage or toxicity (hypervitaminosis D). This indicates it is a concern related to taking too much of the medicine, rather than a common initial side effect.

Q: What are the general expectations about the duration of its effect in the body?

Regulatory safety information notes that the effects of administered vitamin D can persist for two or more months after the cessation of treatment. This is relevant due to the risk profile associated with its storage in the body.

Q: Is it common for doctors to monitor blood levels when a person is on Эргокальциферол?

Yes, regulatory documents necessitate routine blood and urine tests to check for unwanted effects, particularly requiring the monitoring of blood calcium and phosphorus levels. This monitoring is typically advised every two weeks when high therapeutic doses are used.

Q: What is the official definition of vitamin D toxicity in relation to Эргокальциферол?

Vitamin D toxicity is officially defined as Hypervitaminosis D. This condition is primarily characterized by the development of hypercalcemia (high blood calcium levels) and its resulting adverse effects on multiple organ systems.

Q: Is there any difference in how liquids and tablets of Эргокальциферол work?

Official clinical pharmacology sections indicate that the mechanism of action remains the same regardless of the oral form. Both oral liquid solutions and capsules/tablets are metabolized by the body into the same primary active hormonal form to exert their therapeutic effects.

Q: Is it possible to be allergic to the ingredients in Эргокальциферол?

Yes, hypersensitivity (allergy) to the drug or its components is listed as a contraindication for use. Allergic reactions, such as hives or swelling, are also listed among the potential adverse effects in official safety documents.

Q: Can people with high calcium levels in their urine still use Эргокальциферол?

While high blood calcium is an absolute contraindication, official documents require caution and patient monitoring in individuals with certain health conditions. Vitamin D metabolites can increase calcium absorption, which is linked to increased urinary calcium excretion.

Q: Are there any warnings about driving or operating machinery while using Эргокальциферол?

Adverse reaction information lists certain symptoms of toxicity, such as drowsiness and confusion. These effects are noted because they may potentially impair a person's ability to safely drive or operate heavy machinery.

Advertisements

How should Эргокальциферол be stored and disposed of?

Storage and Disposal Requirements for Ergocalciferol

Ergocalciferol, a fat-soluble vitamin, requires specific regulatory storage conditions to maintain stability, as the substance is affected by air and light.

Official Storage Conditions

Requirement Specific Condition
Temperature Store at controlled room temperature (away from excess heat and moisture).
Protection Protect from light; the container must be tight and light-resistant.
Child Safety Keep out of the sight and reach of children.

The medication must be kept in its designated container, which should remain tightly closed when not in use. Certain injectable formulations may require storage in the original outer carton to protect from light.

Disposal

Unused medicinal product and waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Эргокальциферол found in:

A-Z Index: